{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"medRxiv"}],"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T14:15:19Z","timestamp":1774361719113,"version":"3.50.1"},"posted":{"date-parts":[[2023,3,29]]},"group-title":"Addiction Medicine","reference-count":51,"publisher":"openRxiv","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2023,3,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:sec>\n                  <jats:title>Importance<\/jats:title>\n                  <jats:p>Heroin addiction and related mortality impose a devastating toll on society, with little known about the neurobiology of this disease or its treatment. Poor inhibitory control is a common manifestation of prefrontal cortex (PFC) impairments in addiction, and its potential recovery following treatment is largely unknown in heroin (or any drug) addiction.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To study inhibitory control brain activity in iHUD and HC, before and after 15 weeks of inpatient treatment in the former.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Design<\/jats:title>\n                  <jats:p>A longitudinal cohort study (11\/2020-03\/2022) where iHUD and HC underwent baseline and follow-up fMRI scans. Average follow-up duration: 15 weeks.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Setting<\/jats:title>\n                  <jats:p>The iHUD and HC were recruited from treatment facilities and surrounding neighborhoods, respectively.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Participants<\/jats:title>\n                  <jats:p>Twenty-six iHUD [40.6\u00b110.1 years; 7 (29.2%) women] and 24 age-\/sex-matched HC [41.1\u00b19.9 years; 9 (37.5%) women].<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Intervention<\/jats:title>\n                  <jats:p>Following the baseline scan, inpatient iHUD continued to participate in a medically-assisted program for an average of 15 weeks (abstinence increased from an initial 183\u00b1236 days by 65\u00b182 days). The HC were scanned at similar time intervals.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Main Outcomes and Measures<\/jats:title>\n                  <jats:p>\n                    Behavioral performance as measured by the stop-signal response time (SSRT), target detection sensitivity (\n                    <jats:italic>d\u2019<\/jats:italic>\n                    , proportion of hits in go vs. false-alarms in stop trials), and brain activity (blood-oxygen level dependent signal differences) during successful vs. failed stops in the stop signal task.\n                  <\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>\n                    As we previously reported, at time 1 and as compared to HC, iHUD exhibited similar SSRT but impaired\n                    <jats:italic>d\u2019<\/jats:italic>\n                    [\n                    <jats:italic>t<\/jats:italic>\n                    (38.7)=2.37,\n                    <jats:italic>p<\/jats:italic>\n                    =.023], and lower anterior and dorsolateral PFC (aPFC, dlPFC) activity (\n                    <jats:italic>p<\/jats:italic>\n                    &lt;.001). Importantly, at time 2, there were significant gains in aPFC and dlPFC activity in the iHUD (group*session interaction,\n                    <jats:italic>p<\/jats:italic>\n                    =.002); the former significantly correlated with increases in\n                    <jats:italic>d\u2019<\/jats:italic>\n                    specifically in iHUD (\n                    <jats:italic>p<\/jats:italic>\n                    =.012).\n                  <\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Conclusions and Relevance<\/jats:title>\n                  <jats:p>Compared to HC, the aPFC and dlPFC impairments in the iHUD at time 1 were normalized at time 2, which was associated with individual differences in improvements in target detection sensitivity. For the first time in any drug addiction, these results indicate a treatment-mediated inhibitory control brain activity recovery. These neurobehavioral results highlight the aPFC and dlPFC as targets for intervention with a potential to enhance self-control recovery in heroin addiction.<\/jats:p>\n                <\/jats:sec>\n                <jats:sec>\n                  <jats:title>Key points<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Question<\/jats:title>\n                    <jats:p>Does inhibitory control brain function, a common impairment in drug addiction, recover with treatment in inpatient individuals with heroin use disorder (iHUD)?<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Findings<\/jats:title>\n                    <jats:p>In this longitudinal cohort study, 26 inpatient iHUD and 24 healthy controls (HC) performed a stop-signal task during functional MRI twice, separated by an average of 15 weeks. In the iHUD, we found lower anterior and dorsolateral prefrontal cortex (comprising the cognitive control network) signaling at baseline, which increased after 15 weeks of treatment, as associated with behavioral improvements.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Meaning<\/jats:title>\n                    <jats:p>As the opioid epidemic continues, our results indicate potential therapeutic targets to enhance neural function underlying self-control in heroin addiction.<\/jats:p>\n                  <\/jats:sec>\n                <\/jats:sec>","DOI":"10.1101\/2023.03.28.23287864","type":"posted-content","created":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T19:05:40Z","timestamp":1680116740000},"source":"Crossref","is-referenced-by-count":5,"title":["Recovery of inhibitory control prefrontal cortex function in inpatients with heroin use disorder: a 15-week longitudinal fMRI study"],"prefix":"10.64898","author":[{"given":"Ahmet O.","family":"Ceceli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuefeng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre-Olivier","family":"Gaudreault","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalie E.","family":"McClain","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah G.","family":"King","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Greg","family":"Kronberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amelia","family":"Brackett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabriela N.","family":"Hoberman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John H.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric L.","family":"Garland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nelly","family":"Alia-Klein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita Z.","family":"Goldstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"54368","reference":[{"key":"2023040222250417000_2023.03.28.23287864v1.1","unstructured":"Center for Disease Control. Drug Overdose Deaths in the U.S. Top 100,000 Annually. Published November 17, 2021. Accessed June 2, 2022. https:\/\/www.cdc.gov\/nchs\/pressroom\/nchs_press_releases\/2021\/20211117.htm"},{"key":"2023040222250417000_2023.03.28.23287864v1.2","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.159.10.1642"},{"key":"2023040222250417000_2023.03.28.23287864v1.3","doi-asserted-by":"publisher","DOI":"10.1038\/nrn3119"},{"key":"2023040222250417000_2023.03.28.23287864v1.4","doi-asserted-by":"publisher","DOI":"10.1503\/jpn.130052"},{"key":"2023040222250417000_2023.03.28.23287864v1.5","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2016.06.009"},{"key":"2023040222250417000_2023.03.28.23287864v1.6","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-021-01153-9"},{"key":"2023040222250417000_2023.03.28.23287864v1.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2007.03.071"},{"key":"2023040222250417000_2023.03.28.23287864v1.8","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.1237-22.2022"},{"key":"2023040222250417000_2023.03.28.23287864v1.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2022.109319"},{"key":"2023040222250417000_2023.03.28.23287864v1.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2021.109151"},{"key":"2023040222250417000_2023.03.28.23287864v1.11","doi-asserted-by":"publisher","DOI":"10.1016\/j.addbeh.2018.09.005"},{"key":"2023040222250417000_2023.03.28.23287864v1.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2011.10.002"},{"key":"2023040222250417000_2023.03.28.23287864v1.13","doi-asserted-by":"publisher","DOI":"10.1037\/adb0000298"},{"key":"2023040222250417000_2023.03.28.23287864v1.14","doi-asserted-by":"publisher","DOI":"10.1017\/S1092852914000133"},{"issue":"6","key":"2023040222250417000_2023.03.28.23287864v1.15","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1111\/j.1369-1600.2012.00440.x","article-title":"Enhanced midbrain response at 6-month follow-up in cocaine addiction, association with reduced drug-related choice","volume":"17","year":"2012","journal-title":"Addiction Biology"},{"key":"2023040222250417000_2023.03.28.23287864v1.16","doi-asserted-by":"publisher","DOI":"10.3892\/etm.2018.6571"},{"key":"2023040222250417000_2023.03.28.23287864v1.17","doi-asserted-by":"publisher","DOI":"10.1177\/1073858407299288"},{"key":"2023040222250417000_2023.03.28.23287864v1.18","doi-asserted-by":"publisher","DOI":"10.1001\/archgenpsychiatry.2010.60"},{"key":"2023040222250417000_2023.03.28.23287864v1.19","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2020.116582"},{"issue":"Suppl 20","key":"2023040222250417000_2023.03.28.23287864v1.20","first-page":"34","article-title":"The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10","volume":"59","year":"1998","journal-title":"J Clin Psychiatry"},{"key":"2023040222250417000_2023.03.28.23287864v1.21","doi-asserted-by":"publisher","DOI":"10.1016\/0740-5472(92)90062-S"},{"key":"2023040222250417000_2023.03.28.23287864v1.22","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.1992.tb02660.x"},{"key":"2023040222250417000_2023.03.28.23287864v1.23","doi-asserted-by":"publisher","DOI":"10.1016\/0376-8716(93)90042-O"},{"key":"2023040222250417000_2023.03.28.23287864v1.24","doi-asserted-by":"publisher","DOI":"10.3109\/00952998709001515"},{"key":"2023040222250417000_2023.03.28.23287864v1.25","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.1991.tb01879.x"},{"key":"2023040222250417000_2023.03.28.23287864v1.26","doi-asserted-by":"publisher","DOI":"10.1101\/2022.05.27.22275628"},{"key":"2023040222250417000_2023.03.28.23287864v1.27","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.46323"},{"key":"2023040222250417000_2023.03.28.23287864v1.28","doi-asserted-by":"publisher","DOI":"10.3758\/BRM.40.2.479"},{"key":"2023040222250417000_2023.03.28.23287864v1.29","doi-asserted-by":"publisher","DOI":"10.3758\/s13428-014-0458-y"},{"key":"2023040222250417000_2023.03.28.23287864v1.30","doi-asserted-by":"publisher","DOI":"10.1037\/\/0033-295X.91.3.295"},{"key":"2023040222250417000_2023.03.28.23287864v1.31","doi-asserted-by":"publisher","DOI":"10.1006\/nimg.2001.0931"},{"key":"2023040222250417000_2023.03.28.23287864v1.32","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.4682-05.2006"},{"key":"2023040222250417000_2023.03.28.23287864v1.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2011.08.007"},{"key":"2023040222250417000_2023.03.28.23287864v1.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2009.08.037"},{"key":"2023040222250417000_2023.03.28.23287864v1.35","doi-asserted-by":"publisher","DOI":"10.1016\/j.neuroimage.2020.117680"},{"key":"2023040222250417000_2023.03.28.23287864v1.36","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2009.02522.x"},{"key":"2023040222250417000_2023.03.28.23287864v1.37","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.3887-05.2006"},{"key":"2023040222250417000_2023.03.28.23287864v1.38","doi-asserted-by":"publisher","DOI":"10.1038\/20178"},{"key":"2023040222250417000_2023.03.28.23287864v1.39","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0020840"},{"key":"2023040222250417000_2023.03.28.23287864v1.40","doi-asserted-by":"publisher","DOI":"10.1038\/nn1594"},{"key":"2023040222250417000_2023.03.28.23287864v1.41","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.2450-16.2016"},{"key":"2023040222250417000_2023.03.28.23287864v1.42","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2015.11.018"},{"key":"2023040222250417000_2023.03.28.23287864v1.43","doi-asserted-by":"publisher","DOI":"10.1016\/j.brs.2019.12.028"},{"key":"2023040222250417000_2023.03.28.23287864v1.44","doi-asserted-by":"publisher","DOI":"10.1016\/j.ypmed.2012.05.018"},{"key":"2023040222250417000_2023.03.28.23287864v1.45","doi-asserted-by":"publisher","DOI":"10.1111\/acer.13757"},{"key":"2023040222250417000_2023.03.28.23287864v1.46","doi-asserted-by":"publisher","DOI":"10.1007\/s11682-019-00089-5"},{"key":"2023040222250417000_2023.03.28.23287864v1.47","doi-asserted-by":"publisher","DOI":"10.1111\/adb.12403"},{"key":"2023040222250417000_2023.03.28.23287864v1.48","doi-asserted-by":"publisher","DOI":"10.1016\/j.npep.2012.09.002"},{"key":"2023040222250417000_2023.03.28.23287864v1.49","doi-asserted-by":"publisher","DOI":"10.1016\/j.cub.2017.11.018"},{"key":"2023040222250417000_2023.03.28.23287864v1.50","doi-asserted-by":"crossref","unstructured":"Eaton K , Sallee FR , Sah R. Relevance of Neuropeptide Y (NPY) in Psychiatry. Current Topics in Medicinal Chemistry. 7(17):1645\u20131659.","DOI":"10.2174\/156802607782341037"},{"key":"2023040222250417000_2023.03.28.23287864v1.51","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-014-3730-z"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1101\/2023.03.28.23287864","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T19:30:50Z","timestamp":1768505450000},"score":1,"resource":{"primary":{"URL":"http:\/\/medrxiv.org\/lookup\/doi\/10.1101\/2023.03.28.23287864"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,29]]},"references-count":51,"URL":"https:\/\/doi.org\/10.1101\/2023.03.28.23287864","relation":{},"subject":[],"published":{"date-parts":[[2023,3,29]]},"subtype":"preprint"}}